AI Networking Cookbook: Practical recipes for AI-assisted network automation and development
TL;DR
This review systematically integrates advances in STAMBPL1 biology from structural to translational studies, highlighting its promise as a therapeutic target for precision cancer therapy.
Prostate cancer (PC) is one of the most common male cancers. Cancer cells are well known for their capacity to avoid programed cell death (PCD) via a variety of molecular pathways, allowing them to survive oncogenic stress and therapeutic challenges. Although oncogenic splicing factors are frequently dysregulated in tu...
DUBs function as central signaling hubs orchestrating malignant progression, treatment resistance, and immune evasion in breast cancer, positioning them as promising prognostic biomarkers and therapeutic targets.
Receptor-interacting protein kinase 1 (RIPK1) mediates cell survival, inflammation, and cell death, and its kinase-independent scaffolding function drives tumor progression and therapeutic resistance, which cannot be eliminated by conventional RIPK1 kinase inhibitors. To overcome this limitation, we adopted proteolysis...
S-phase kinase-associated protein 2 (SKP2), a key substrate-recognition subunit of the Skp1-Cul1-F-box (SCF) E3 ubiquitin ligase complex, promotes the ubiquitin–proteasome-mediated degradation of tumor suppressors such as p27Kip1 and p21(Cip1/Waf1). Through these activities, SKP2 regulates critical cellular processes,...
The ubiquitin-specific peptidase 42 (USP42) is a cysteine-dependent deubiquitinase with pro-tumorigenic roles in several cancers. In lung adenocarcinoma (LUAD), elevated USP42 expression correlates with advanced stage and poor survival, mirroring the prognostic impact of prostaglandin-endoperoxide synthase 2 (PTGS2) ov...
It is proposed that UBA1 functions as a proteostasis-innate immunity checkpoint whose biological output is determined by residual enzymatic activity, subcellular distribution, lineage context, and clone size and suggests a mechanism-based approach to therapeutic intervention in VEXAS syndrome and malignancy.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.